We are Neuraly.
Neuraly is a clinical-stage biotechnology company whose mission is to translate scientific discoveries in neurology into new drugs that can radically improve and prolong the lives of people suffering from the devastating consequences of diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and other neurodegenerative disorders. The company is leveraging a deep understanding of the role of glia biology in neuroinflammation and neuroprotection to advance a risk-diversified product portfolio for PD and AD. Neuraly is a subsidiary of D&D Pharmatech, a clinical stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty and biotechnology veterans. Please visit http://www.ddpharmatech.com/
NLY01, the lead asset, is a long-acting, microglia-targeted GLP-1R agonist that targets microglia/astrocytes-induced neuroinflammation and has proven strong therapeutic efficacy in preclinical models of both PD and AD. NLY01 is currently in Phase 2 in early Parkinson’s and Alzheimer’s patients. Neuraly is advancing IND-enabling studies of follow-up small molecule candidates with different but complementary mechanisms for PD and AD.
“Currently, there aren’t any treatments that reverse, stop, or even slow neurodegeneration in diseases like Parkinson’s and Alzheimer’s. The treatments that do exist – all symptomatic – provide only temporary improvement in motor and cognitive function, but even these become less effective over time. We believe that the science supports NLY01 as a potential disease-modifying therapy capable of slowing the progression of disease.”
— Dr. Seulki Lee, CEO of Neuraly
OUR MISSION, VISION, & CORE VALUES
Mission: To develop innovative treatments to help people live better, fuller, and longer lives.
Vision: Respected leader in the discovery and development of breakthrough medicines.
Core Values: Principles and standards that are most important to our company.
• Pioneering: We are committed to innovation, to push the boundaries of scientific discovery to develop groundbreaking treatments and new approaches to address unmet medical needs by collaborating with academia, research institutions, and other companies.
• Science-Driven: We base our key decisions and actions on scientific data and research, which reflects our commitment to the pursuit of understanding through scientific methods while also adapting to new and evolving scientific evidence.
• Integrity: We strive to always do the right thing and to act ethically, including rigorously adhering to scientific principles. Part of being integral means taking accountability for our own actions and decisions, a strong commitment to quality, treating others with respect, and creating transparency in all aspects of the business.
• Collaboration: We foster teamwork and a collaborative culture that creates synergy, resulting in a combined effort with greater results than those achieved individually while ensuring that everyone feels included and valued.